SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-033247
Filing Date
2024-03-12
Accepted
2024-03-12 07:15:26
Documents
15
Period of Report
2024-03-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm248359d1_8k.htm   iXBRL 8-K 26790
2 EXHIBIT 99.1 tm248359d1_ex99-1.htm EX-99.1 81595
  Complete submission text file 0001104659-24-033247.txt   294999

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA btai-20240312.xsd EX-101.SCH 3048
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE btai-20240312_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btai-20240312_pre.xml EX-101.PRE 22381
16 EXTRACTED XBRL INSTANCE DOCUMENT tm248359d1_8k_htm.xml XML 3496
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38410 | Film No.: 24740174
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)